Evidence map›Paper›PMID 26798584›Full record

ReviewTranslational lung cancer research2015

Immunotherapy meets targeted therapy: will this team end the war against cancer?

Daniela Morales-Espinosa, Silvia García-Román, Cristina Teixidó, Niki Karachaliou, Rafael Rosell

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Translational lung cancer research, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Daniela Morales-Espinosa1 Rosell Oncology Institute, Quirón-Dexeus University Hospital, Barcelona, Spain ; 2 Pangaea Biotech, Barcelona, Spain ; 3 Institut Quimic de Sarriá, Barcelona, Spain ; 4 Institut Catalá d'Oncologia, Badalona, Spain.
Silvia García-Román1 Rosell Oncology Institute, Quirón-Dexeus University Hospital, Barcelona, Spain ; 2 Pangaea Biotech, Barcelona, Spain ; 3 Institut Quimic de Sarriá, Barcelona, Spain ; 4 Institut Catalá d'Oncologia, Badalona, Spain.
Cristina Teixidó1 Rosell Oncology Institute, Quirón-Dexeus University Hospital, Barcelona, Spain ; 2 Pangaea Biotech, Barcelona, Spain ; 3 Institut Quimic de Sarriá, Barcelona, Spain ; 4 Institut Catalá d'Oncologia, Badalona, Spain.
Niki Karachaliou1 Rosell Oncology Institute, Quirón-Dexeus University Hospital, Barcelona, Spain ; 2 Pangaea Biotech, Barcelona, Spain ; 3 Institut Quimic de Sarriá, Barcelona, Spain ; 4 Institut Catalá d'Oncologia, Badalona, Spain.
Rafael Rosell1 Rosell Oncology Institute, Quirón-Dexeus University Hospital, Barcelona, Spain ; 2 Pangaea Biotech, Barcelona, Spain ; 3 Institut Quimic de Sarriá, Barcelona, Spain ; 4 Institut Catalá d'Oncologia, Badalona, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cancer treatment as we know it today has dramatically changed over the last couple of decades. It has moved from non-specific treatment to personalized approaches. As oncologist, we now have further understanding of the processes leading to carcinogenesis; this has led to develop new therapeutic options. We have cytotoxic treatments, targeted therapy and in recent years, immunotherapy; the time to "mix and match" has begun.

Indexed as

cancercombination therapyImmunotherapypersonalized treatmenttargeted therapy

Identifiers

PMID26798584
PMCPMC4700229

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.